| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 16 | 2024 | 1776 | 1.620 |
Why?
|
| Dacarbazine | 6 | 2017 | 502 | 1.170 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2021 | 2386 | 0.920 |
Why?
|
| Dysmenorrhea | 1 | 2023 | 16 | 0.860 |
Why?
|
| Kidney Neoplasms | 5 | 2021 | 3108 | 0.830 |
Why?
|
| Benzimidazoles | 2 | 2015 | 437 | 0.780 |
Why?
|
| Integrins | 3 | 2010 | 275 | 0.690 |
Why?
|
| Tuberous Sclerosis | 1 | 2021 | 145 | 0.660 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2017 | 605 | 0.600 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2017 | 7 | 0.600 |
Why?
|
| DNA Modification Methylases | 2 | 2015 | 176 | 0.590 |
Why?
|
| DNA Repair Enzymes | 2 | 2015 | 238 | 0.560 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2017 | 520 | 0.550 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2023 | 7783 | 0.550 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 4821 | 0.510 |
Why?
|
| Brain Neoplasms | 9 | 2024 | 4958 | 0.500 |
Why?
|
| Interferon-beta | 4 | 2008 | 109 | 0.460 |
Why?
|
| Image Enhancement | 2 | 2015 | 553 | 0.450 |
Why?
|
| Laparoscopy | 1 | 2023 | 1302 | 0.440 |
Why?
|
| Whole Body Imaging | 1 | 2014 | 120 | 0.430 |
Why?
|
| Contrast Media | 4 | 2022 | 1499 | 0.430 |
Why?
|
| Gadolinium | 1 | 2014 | 169 | 0.430 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 232 | 0.420 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2024 | 3917 | 0.410 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2015 | 1903 | 0.360 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2018 | 7895 | 0.340 |
Why?
|
| Immunoconjugates | 2 | 2024 | 314 | 0.330 |
Why?
|
| Blood-Brain Barrier | 4 | 2022 | 251 | 0.330 |
Why?
|
| Radiation Dosage | 4 | 2023 | 1042 | 0.330 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2009 | 262 | 0.310 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 1174 | 0.310 |
Why?
|
| Cell Movement | 3 | 2010 | 2472 | 0.300 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2024 | 437 | 0.290 |
Why?
|
| Multidetector Computed Tomography | 2 | 2022 | 147 | 0.280 |
Why?
|
| DNA Methylation | 3 | 2019 | 2765 | 0.280 |
Why?
|
| Multiple Sclerosis | 5 | 2009 | 375 | 0.280 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2008 | 39 | 0.280 |
Why?
|
| src-Family Kinases | 1 | 2009 | 487 | 0.270 |
Why?
|
| Adjuvants, Immunologic | 3 | 2007 | 695 | 0.260 |
Why?
|
| Brain | 7 | 2022 | 4208 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 5408 | 0.260 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2017 | 162 | 0.250 |
Why?
|
| Mice, Nude | 6 | 2021 | 4329 | 0.250 |
Why?
|
| Humans | 49 | 2024 | 270740 | 0.250 |
Why?
|
| Bystander Effect | 1 | 2024 | 22 | 0.240 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 3707 | 0.210 |
Why?
|
| Quinolones | 1 | 2024 | 163 | 0.210 |
Why?
|
| Pelvic Pain | 1 | 2023 | 49 | 0.210 |
Why?
|
| Myometrium | 1 | 2023 | 82 | 0.210 |
Why?
|
| Ataxia Telangiectasia | 1 | 2022 | 62 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 5257 | 0.200 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2024 | 327 | 0.200 |
Why?
|
| Cell Line, Tumor | 9 | 2024 | 14849 | 0.190 |
Why?
|
| Abdomen | 1 | 2023 | 347 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 3658 | 0.190 |
Why?
|
| Luminescent Measurements | 1 | 2021 | 158 | 0.190 |
Why?
|
| Isoxazoles | 1 | 2021 | 81 | 0.190 |
Why?
|
| Indazoles | 2 | 2020 | 310 | 0.190 |
Why?
|
| Azabicyclo Compounds | 1 | 2021 | 40 | 0.180 |
Why?
|
| Pyrimidines | 3 | 2020 | 3669 | 0.180 |
Why?
|
| ErbB Receptors | 3 | 2024 | 2375 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2022 | 4961 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 152 | 0.170 |
Why?
|
| Female | 25 | 2024 | 148940 | 0.170 |
Why?
|
| Sulfonamides | 2 | 2020 | 1933 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2019 | 126 | 0.160 |
Why?
|
| Animals | 17 | 2024 | 61956 | 0.160 |
Why?
|
| Signal Transduction | 5 | 2024 | 12103 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2023 | 13414 | 0.160 |
Why?
|
| Mice | 14 | 2024 | 35600 | 0.160 |
Why?
|
| Pyrazines | 1 | 2021 | 510 | 0.160 |
Why?
|
| Up-Regulation | 3 | 2015 | 2422 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 9042 | 0.150 |
Why?
|
| Random Allocation | 2 | 2017 | 741 | 0.150 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2022 | 382 | 0.150 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 7914 | 0.150 |
Why?
|
| Uterus | 1 | 2023 | 798 | 0.150 |
Why?
|
| DNA Repair | 3 | 2024 | 1909 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 398 | 0.140 |
Why?
|
| Chromones | 1 | 2017 | 121 | 0.140 |
Why?
|
| Adult | 17 | 2023 | 82040 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 3409 | 0.140 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2017 | 76 | 0.140 |
Why?
|
| Pyridines | 1 | 2024 | 1313 | 0.140 |
Why?
|
| Paraparesis, Tropical Spastic | 2 | 2006 | 7 | 0.140 |
Why?
|
| Quinazolines | 1 | 2021 | 956 | 0.130 |
Why?
|
| Male | 19 | 2023 | 128315 | 0.130 |
Why?
|
| Middle Aged | 14 | 2023 | 90352 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 656 | 0.130 |
Why?
|
| Phthalazines | 1 | 2017 | 262 | 0.130 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 522 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 368 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 840 | 0.120 |
Why?
|
| Iridium Radioisotopes | 1 | 2014 | 57 | 0.120 |
Why?
|
| Pyridazines | 1 | 2017 | 324 | 0.120 |
Why?
|
| Thyrotropin | 1 | 2014 | 124 | 0.110 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 95 | 0.110 |
Why?
|
| Survivors | 1 | 2019 | 1021 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 1580 | 0.110 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 481 | 0.110 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 30998 | 0.110 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 323 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 16689 | 0.110 |
Why?
|
| Retrospective Studies | 9 | 2022 | 39890 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 1542 | 0.100 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2012 | 10 | 0.100 |
Why?
|
| Models, Biological | 3 | 2010 | 3194 | 0.100 |
Why?
|
| DNA Damage | 3 | 2017 | 1989 | 0.100 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 322 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2016 | 799 | 0.100 |
Why?
|
| Kidney | 1 | 2021 | 2121 | 0.100 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2012 | 89 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4831 | 0.100 |
Why?
|
| Imidazoles | 1 | 2017 | 1065 | 0.090 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2011 | 28 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 631 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1076 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2024 | 4942 | 0.090 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 183 | 0.090 |
Why?
|
| Cell Adhesion | 2 | 2010 | 1028 | 0.090 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2011 | 116 | 0.090 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 14617 | 0.090 |
Why?
|
| Fibroblasts | 2 | 2014 | 1654 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 1269 | 0.090 |
Why?
|
| Mutation | 3 | 2024 | 15912 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2009 | 12 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2009 | 29 | 0.090 |
Why?
|
| Osteosarcoma | 1 | 2017 | 950 | 0.080 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2009 | 24 | 0.080 |
Why?
|
| Disease Progression | 2 | 2018 | 6867 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2015 | 602 | 0.080 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2009 | 27 | 0.080 |
Why?
|
| Interferon beta-1b | 2 | 2005 | 6 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 3476 | 0.080 |
Why?
|
| Treatment Outcome | 7 | 2020 | 33737 | 0.080 |
Why?
|
| Aortic Valve | 1 | 2012 | 445 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2017 | 2123 | 0.080 |
Why?
|
| Histones | 2 | 2017 | 1513 | 0.080 |
Why?
|
| Cricetulus | 1 | 2009 | 214 | 0.080 |
Why?
|
| Endothelium | 1 | 2009 | 156 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2009 | 1810 | 0.080 |
Why?
|
| CHO Cells | 1 | 2009 | 320 | 0.080 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2009 | 110 | 0.080 |
Why?
|
| Liver | 1 | 2018 | 3086 | 0.080 |
Why?
|
| Aged | 8 | 2019 | 73333 | 0.080 |
Why?
|
| Cannabinoids | 1 | 2009 | 43 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 1739 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 6177 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 3438 | 0.080 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 163 | 0.080 |
Why?
|
| Cricetinae | 1 | 2009 | 769 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2014 | 5694 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2014 | 1005 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2012 | 847 | 0.070 |
Why?
|
| Young Adult | 4 | 2019 | 22251 | 0.070 |
Why?
|
| Genomics | 1 | 2018 | 2835 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2010 | 658 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2008 | 451 | 0.070 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2006 | 103 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2015 | 1546 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 1109 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2021 | 1461 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 2665 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 676 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 5162 | 0.060 |
Why?
|
| DNA End-Joining Repair | 1 | 2024 | 92 | 0.060 |
Why?
|
| Forearm | 1 | 2003 | 69 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2009 | 762 | 0.050 |
Why?
|
| Hand Deformities, Congenital | 1 | 2003 | 95 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 623 | 0.050 |
Why?
|
| Hand | 1 | 2003 | 175 | 0.050 |
Why?
|
| Cell Survival | 2 | 2019 | 3063 | 0.050 |
Why?
|
| Luciferases, Firefly | 1 | 2021 | 40 | 0.050 |
Why?
|
| Infusion Pumps | 1 | 2021 | 60 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 4481 | 0.050 |
Why?
|
| Luciferases | 1 | 2021 | 460 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10708 | 0.040 |
Why?
|
| Neoplasm Proteins | 2 | 2022 | 3345 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2021 | 927 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2018 | 1838 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2022 | 522 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2018 | 206 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 164 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2017 | 78 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 1286 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2017 | 237 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 408 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 1553 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 4372 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 7381 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 5056 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 729 | 0.030 |
Why?
|
| Protein Modification, Translational | 1 | 2014 | 5 | 0.030 |
Why?
|
| Miniaturization | 1 | 2014 | 49 | 0.030 |
Why?
|
| Graves Disease | 1 | 2014 | 48 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 4048 | 0.030 |
Why?
|
| Renal Veins | 1 | 2014 | 63 | 0.030 |
Why?
|
| Transfection | 1 | 2019 | 3117 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2010 | 1038 | 0.030 |
Why?
|
| Computer-Aided Design | 1 | 2014 | 76 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2014 | 322 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 1248 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2015 | 318 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 2014 | 194 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2019 | 7238 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 350 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 1441 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2014 | 531 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 5728 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2008 | 2057 | 0.020 |
Why?
|
| Swiss 3T3 Cells | 1 | 2011 | 5 | 0.020 |
Why?
|
| Acetylation | 1 | 2012 | 515 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2011 | 82 | 0.020 |
Why?
|
| Equipment Design | 1 | 2014 | 1197 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 118 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 255 | 0.020 |
Why?
|
| Dermis | 1 | 2010 | 63 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 3485 | 0.020 |
Why?
|
| Transcriptome | 1 | 2019 | 1963 | 0.020 |
Why?
|
| Prognosis | 2 | 2019 | 22505 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 625 | 0.020 |
Why?
|
| Algorithms | 1 | 2022 | 3891 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 647 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 1133 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 709 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 964 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2012 | 410 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2014 | 1050 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 15218 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 454 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 122 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1552 | 0.020 |
Why?
|
| Dogs | 1 | 2011 | 1160 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2009 | 88 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 266 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2014 | 798 | 0.020 |
Why?
|
| Dronabinol | 1 | 2009 | 41 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 2033 | 0.020 |
Why?
|
| Antigens | 1 | 2009 | 281 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2009 | 279 | 0.020 |
Why?
|
| Cannabidiol | 1 | 2009 | 43 | 0.020 |
Why?
|
| Radiometry | 1 | 2014 | 1020 | 0.020 |
Why?
|
| Time | 1 | 2008 | 183 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2008 | 117 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 617 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 733 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 5149 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 1685 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 234 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 453 | 0.020 |
Why?
|
| Interferon beta-1a | 1 | 2007 | 23 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 453 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 5315 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2008 | 610 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 1383 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2069 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 342 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 2255 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 3584 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12541 | 0.020 |
Why?
|
| HTLV-I Infections | 1 | 2005 | 17 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 2115 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 3597 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 809 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 905 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2009 | 902 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 3216 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2008 | 672 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2196 | 0.010 |
Why?
|
| Age of Onset | 1 | 2007 | 853 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 1145 | 0.010 |
Why?
|
| Viral Load | 1 | 2006 | 485 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 4567 | 0.010 |
Why?
|
| Neoplasms | 1 | 2010 | 15927 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2014 | 6390 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2011 | 1875 | 0.010 |
Why?
|
| Cadaver | 1 | 2003 | 202 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 6685 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2009 | 2580 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 1710 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2009 | 1563 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 3530 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 1312 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6256 | 0.010 |
Why?
|
| Time Factors | 2 | 2007 | 13006 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2005 | 718 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 17888 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 1690 | 0.010 |
Why?
|
| Patient Selection | 1 | 2006 | 2025 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 14012 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 9470 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 4492 | 0.010 |
Why?
|